- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Anupam Rasayan reported strong 9MFY26 financials: Revenue at INR 1,730 Cr (+84% YoY), EBITDA at INR 402 Cr (+53% YoY), and PAT at INR 166 Cr (+71% YoY). Q3FY26 also saw robust growth. Agro demand is recovering, while Pharma and Performance Material segments showed strong momentum. The company is acquiring US-based Jayhawk Fine Chemicals for direct US manufacturing, boosting access to high-value markets like semiconductors and EVs. This acquisition is expected to be EPS accretive. Management focuses on pipeline commercialization and supply chain strength. Working capital days target sub-180 by FY27, indicating a positive outlook for sustained growth.